Extracellular Matrix in Synthetic Hydrogel-based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 inhibitors.

Following treatment with androgen receptor (AR) pathway inhibitors, ∼20% of prostate cancer patients progress by shedding their AR dependence. These tumors undergo epigenetic reprogramming turning castration-resistant prostate cancer adenocarcinoma (CRPC-Adeno) into neuroendocrine prostate cancer (CRPC-NEPC).